

UnivEsanté – Swall-EHPAD

Swallis Medical had the opportunity to share its experience in the field at the **UnivEsanté** round table "How to make innovation in e-health an oasis for citizens". Our CEO, **Linda Nicolini**, attended the **Swall- EHPAD** clinical trial results presentation meeting. We're delighted to share them with you!



*From left to right:
Sylvie Cabanes - ARS Occitanie,
Frederic Vitalis - Direction EHPAD Arpavie Sète,
Linda Nicolini - CEO Swallis Medical,
Dr Nadia Mazouz - Direction Médicale Arpavie*

1. **The acceptability** of the Swallis DSA™ device by residents is validated: All participants accepted the installation of the device, and over 85% kept it with them throughout their evaluation.

2. Prior **training** and repeated use of the device ensure that it is easy for the care team to use independently.

3. Even **from a distance**, the speech therapist was able to make recommendations for each resident. In particular, almost half of the residents needed help with meals, and 1/4 needed changes to their diet or drinks. We found a 70% **concordance** on **dietary recommendations** when comparing the observations for each resident of the speech therapist in presence with those of the speech therapist at a distance.

Clinical assessment of dysphagia using the Swallis DSA™ device represents a feasible alternative to face-to-face assessment. And this device paves the way for remote swallowing assessment, enabling the resident to be assessed in his or her usual living context.

The EHPADs who took part in the study are unanimous: the Swallis solution meets an unmet public health need: **remote monitoring of swallowing disorders**.